Pasar al contenido principal

Miquel Vila Bover

I am an ICREA Professor and I lead the Research Group on Neurodegenerative Diseases at the Vall d'Hebron Research Institute (VHIR)

Instituciones de las que forman parte

Jefe de grupo
Enfermedades Neurodegenerativas
Vall Hebron Institut de Recerca
Miquel Vila Bover

Miquel Vila Bover

Miquel Vila Bover

Instituciones de las que forman parte

Jefe de grupo
Enfermedades Neurodegenerativas
Vall Hebron Institut de Recerca

I am an ICREA Professor and I lead the Research Group on Neurodegenerative Diseases at the Vall d'Hebron Research Institute (VHIR)

I have a degree in Medicine and Surgery from the University of Barcelona (1993) and a PhD in Neuroscience from the University of Paris 6 (1998). My doctoral work carried out in the laboratory of experimental neurology at the Salpetriere Hospital in Paris (1993-98) contributed to establishing the subthalamic nucleus as the main therapeutic target for the surgical treatment of Parkinson's disease with deep brain stimulation. From 1998 to 2005 I worked at the Movement Disorders Unit of Columbia University in New York (USA), initially as a postdoctoral researcher and from 2001 as an Assistant Professor of Neurology, focusing on the study of the mechanisms of neuronal death in Parkinson's disease to identify new therapeutic targets for this currently incurable neurodegenerative disorder.

In 2006 I moved to Barcelona as a Professor at ICREA (Catalan Institute of Research and Advanced Studies) to create and lead a new research group in neurodegenerative diseases at the Vall d'Hebron Research Institute (VHIR). Our group is now part of the Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED) and the Aligning Science Across Parkinson's Collaborative Research Network (ASAP-CRN).

I am also an Associate Professor at the Autonomous University of Barcelona, Principal Investigator at CIBERNED, Coordinating Lead PI at ASAP-CRN and member of the Steering Committees of the World Parkinson Coalition and the Basic Science Special Interest Group of the International Parkinson and Movement Disorder Society.

Líneas de investigación

Alpha-synuclein involvement in Parkinson's disease

Formation and accumulation of abnormal protein aggregates are a central hallmark of several neurodegenerative diseases. In Parkinson’s disease (PD), the aggregation-prone protein á-synuclein accumulates in several areas of the central and peripheral nervous system. Pathological á-synuclein accumulation in PD can result from (i) abnormally increased á-synuclein expression, (ii) defective intracellular clearance of á-synuclein protein, (iii) progressive self-propagation and spreading of pathological á-synuclein between interconnected brain areas. Targeting á-synuclein pathological changes may provide therapeutic benefit to delay, halt or prevent neuronal dysfunction and degeneration in PD.

IP: Miquel Vila Bover

Neuromelanin and Parkinson's disease

In Parkinson's disease (PD), there is a selective degeneration of neurons that contain a dark-brown pigment called neuromelanin, especially dopaminergic neurons of the substantia nigra, which leads to the classical motor symptoms of the disease. However, the physiological significance of neuromelanin and its potential contribution to PD pathogenesis remain unknown.

IP: Miquel Vila Bover

Identification of biomarkers of prodromal Parkinson's disease

Despite intensive efforts towards understanding the aetiology/pathogenesis of Parkinson's disease (PD) and the development of novel therapeutic approaches for this neurodegenerative condition, the current treatment for PD remains symptomatic and yet far from modifying disease onset or progression. Before the manifestation of the classical motor symptoms, PD patients present with non-motor symptoms in a prodromal phase. The identification of deregulated molecular pathways or genes in peripheral blood and/or cerebrospinal fluid from these prodromal patients may help develop potential biomarkers for the early detection, diagnosis, risk assessment and/or progression of PD, which are currently lacking, as well as to stratify patients at very early stages to apply more specific, personalized disease-modifying treatments.

IP: Miquel Vila Bover, Ariadna Laguna Tuset

Regeneration of dopaminergic neurons in Parkinson's disease via cell fusion-mediated reprogramming

Co-PI: Pia Cosma, CRG.


Given the current lack of disease-modifying therapies for Parkinson’s disease (PD), we are exploring whether cell-fusion-mediated regeneration of dopaminergic neurons can be achieved, for therapeutic purposes, in experimental animal models of PD after transplantation of Wnt-activated haematopoietic stem and progenitor cells (HSPCs).

IP: Miquel Vila Bover

Proyectos

Red de Investigación MitoNED: (Dis)función mitocondrial en enfermedades neurodegenerativas

IP: Miquel Vila Bover
Colaboradores: -
Entidad financiadora: Ministerio de Ciencia e Innovación-MICINN
Financiación: 0.01
Referencia: RED2022-134786-T
Duración: 01/06/2023 - 31/05/2025

Ministerio de Ciencia

Malalties neurodegeneratives

IP: Miquel Vila Bover
Colaboradores: Jorge Hernández Vara, Joan Compte Barrón, Marta Martínez Vicente, Jordi Bove Badell, Eddie Pradas Gracia, Maria Camprodon Gomez, Marina Lorente Picón, Laura Castillo Ribelles, Oriol de Fabregues-Boixar Nebot, Javier Hoyo Pérez, Ariadna Laguna Tuset, Thais Cuadros Arasa, Jordi Riera Heredia, David Ramos Vicente, Marta Montpeyó Garcia-Moreno, Helena Xicoy Cortada, Alba Nicolau Vera, Marta González Sepúlveda, Joana Margalida Cladera Sastre, Annabelle Parent, Daniela Samaniego Toro, Daniela Samaniego Toro
Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca
Financiación: 40000
Referencia: 2021 SGR 00784
Duración: 01/01/2022 - 30/06/2025

MECANISMOS MOLECULARES DE NEURODEGENERACION LIGADA A LA NEUROMELANINA EN LA ENFERMEDAD DE PARKINSON Y ENVEJECIMIENTO CEREBRAL

IP: Miquel Vila Bover
Colaboradores: Gerard Roch Alba, Miriam Izquierdo Sans
Entidad financiadora: Ministerio de Ciencia e Innovación-MICINN
Financiación: 99260
Referencia: PRE2021-098300
Duración: 01/07/2022 - 30/06/2026

Ministerio de Ciencia

Activity and connectivity drive neuronal vulnerability and disease progression in Parkinson's disease

IP: Miquel Vila Bover
Colaboradores: Joan Compte Barrón, Javier Hoyo Pérez, Gerard Roch Alba, Marta González Sepúlveda, Ariadna Laguna Tuset, Joana Margalida Cladera Sastre
Entidad financiadora: Michael J. Fox Foundation
Financiación: 1269495.05
Referencia: ASAP_MJFF2021
Duración: 01/11/2021 - 31/10/2024

Noticias relacionadas

El encuentro científico conmemoró los 10 años del CIBER con el objetivo de fomentar la colaboración y la puesta en marcha de nuevos proyectos.

Son estudios centrados en osteoporosis y enfermedad de Gaucher.

La III Jornada de Parkinson de Vall d’Hebron se ha centrado en la evolución durante los 40 años de la Unidad de Trastornos del Movimiento del hospital y en el testimonio cercano de pacientes con la enfermedad.

Profesionales relacionados

Roman Serrat  Reñe

Roman Serrat Reñe

Investigador postdoctoral
Enfermedades Neurodegenerativas
Leer más
Maria Antonia Arbos  Via

Maria Antonia Arbos Via

Investigador/a principal
Cirugía General
Leer más
Raquel Albertos  Martell

Raquel Albertos Martell

Shock, Disfunción Orgánica y Resucitación
Leer más
Maria Pilar Mancera Aroca

Maria Pilar Mancera Aroca

Tècnic/a Superior Recerca
Unidad de Alta Tecnología (UAT)
Core Facilities Preclínicos
Dirección de Estrategia Externa
Leer más

Suscríbete a nuestros boletines y forma parte de la vida del Campus

Vall d'Hebron Barcelona Hospital Campus es un parque de referencia mundial donde la asistencia, la investigación, la docencia y la innovación se dan la mano.